Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 74
Selected: 0
NCT IDTitle
NCT02881242Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
NCT01990196Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
NCT05918263Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial
NCT02499835Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
NCT00953576Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
NCT01703065Cabozantinib in Men With Castration-Resistant Prostate Cancer
NCT05766371Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
NCT04457232Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation
NCT05471414Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer
NCT00651222Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy
NCT07050433Correlate Biomarkers for the SYNERGY- 201 Study
NCT01417182Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer
NCT01379742Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT05113537Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
NCT04430192Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
NCT02269982Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY
NCT02478125Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer
NCT03358563Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer
NCT05320406RElugolix VErsus LeUprolide Cardiac Trial
NCT02080650Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)
NCT05445609Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT03492424Ablative Therapy in the Management of Prostate Cancer
NCT02300324The Bioavailability Of Sulforaphane From Broccoli Soups Study (BOBS)
NCT03392428A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer
NCT02985021Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
NCT03761160Mobile Health App to Mitigate the Metabolic Effects of Androgen Deprivation Therapy
NCT03477864Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
NCT06171139Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
NCT05327465Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
NCT01961713Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy
NCT02025413Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method
NCT04447703Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study
NCT03007732Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
NCT01289067Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca
NCT05702619Hypoxia-driven Prostate Cancer Genomics (HYPROGEN)
NCT05435495Mechanisms of Resistance to PSMA Radioligand Therapy
NCT02470936Web-based Lifestyle Trial Among Men With Prostate Cancer: Prostate 8
NCT03957252Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer
NCT06714630The PROSECCA Study, Answering New Questions in Prostate Cancer
NCT03532217Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
NCT02735252PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
NCT02582697Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
NCT02445976Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.
NCT06200974Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
NCT02677376Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC
NCT02159690A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
NCT06046040TmPSMA-02 in mCRPC
NCT04116775Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
NCT04343885In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy
NCT06059118Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer